High Sensitivity C - Reactive Protein and Insulin Resistance in Women with Polycystic Ovary Syndrome
Background: Polycystic Ovary Syndrome (PCOS) characterised by anovulation, polycystic ovaries and hyperandrogenism also leads to metabolic abnormalities such as insulin resistance (IR), deranged lipid profile, hypertension and a low-grade chronic inflammation. These factors are known to increase risk for cardiovascular diseases. This study aimed to compare various biochemical parameters between women with PCOS and age matched healthy controls.
Methods: Total 80 women diagnosed with PCOS were investigated for fasting plasma glucose, serum insulin, Insulin resistance (homeostasis model assessment, HOMA-IR), and hs-CRP and compared with 40 apparently healthy women. Cases of PCOS were divided in two groups based on BMI: PCOS with BMI 18.5 – 24.99 kg/m2 and PCOS with BMI ≥ 25 kg/m2.
Results: Serum insulin levels and HOMA-IR values were significantly (p<0.05) higher in women with PCOS than controls. Levels of hs-CRP were also significantly higher in women with PCOS as compared to controls.
Conclusions: Early recognition of risk factors for cardiovascular disease in PCOS women is important from clinical and public health perspective.
2. Gonzalez F, Rote NS, Minium J, Kirwan JP. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism. 2009;58(7): 954-962.
3. Mohamadin AM, Habib FA, Al-Saggaf AA. Cardiovascular disease markers in women with polycystic ovary syndrome with emphasis on asymmetric dimethylarginine and homocysteine. Ann Saudi Med. 2010;30(4):278-283.
4. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-47.
5. Homeostasis model assessment. [last modified on 2017 June 11. Cited 2017 July 18]. Available from: Wikipedia, the free encyclopedia.
6. Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol. 2009;2(4):232-239.
7. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41.
8. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83(5):1454-1460.
9. Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome: a review analysis. Hippokratia 2009;13(2):90-92.
10. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocr Pract. 2005;11(2):126-34.
11. Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95(3):1048-58.
12. Shishehbor MH, Bhatt DL, Topol EJ. Using C-reactive protein to asses cardiovascular disease risk. Clev Clin J Med 2003;70(7):634-640.
13. Tosi F, Dorizzi R, Castello R, Maffeis C, Spiazzi G, Zoppini G, et al. Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome. Eur J Endocrinol. 2009;161(5): 737-745.
14. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab. 2004;89(11):5592-5596.
15. Sandeep S, Gokulakrishnan K, Velmurugan K, Deepa M, Mohan V. Visceral & subcutaneous abdominal fat in relation to insulin resistance & metabolic syndrome in non-diabetic south Indians. Indian J Med Res. 2010;131:629-635.
16. Insulin resistance. 2009 Dec. [Last modified 2012 Sep 11, Cited 2012 Oct 2]. Available from: Wikipedia, the free encyclopedia.
17. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab. 2004;89(5):2160-2165.
18. Orio F, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L, et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(1):2-5.
19. Gelaye B, Revilla L, Lopez T, Suarez L, Sanchez SE, Hevner K, et al. Association between insulin resistance and c-reactive protein among Peruvian adults. Diabetol Metab Syndr. 2010;2(1):1-6.
20. Karoli R, Fatima J, Siddiqi Z, Vatsal P, Sultania AR, Maini S. Study of early atherosclerotic markers in women with polycystic ovary syndrome. Indian J Endocrinol Metab. 2012;16(6):1004-1008.
21. Oh JY, Lee JA, Lee H, Oh JY, Sung YA, Chung H. Serum C-reactive protein levels in normal-weight polycystic ovary syndrome. Korean J Intern Med. 2009;24(4):350-355.
22. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86(6):2453-2455.
Copyright (c) 2017 International Archives of BioMedical and Clinical Research
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.